VivoSeq
Oncology

Advanced Solid Tumours

0

Pipeline Programs↗

33

Active Trials↗

27

Companies Involved↗

Advanced Solid Tumours is an early-stage landscape with 0 programs across 27 companies. The most active players are AstraZeneca, Boehringer Ingelheim, LaNova Medicines Limited.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalL

LaNova Medicines Limited

0 programs

PreclinicalS

Suzhou BlueHorse Therapeutics Co., Ltd.

0 programs

PreclinicalOrion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

0 programs

PreclinicalJiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

109

clinical trials

Completed58 · 53%
Recruiting27 · 25%
Terminated12 · 11%
Unknown status6 · 6%
Not yet recruiting3 · 3%
Active, not recruiting3 · 3%

Clinical Trials

Trial Activity

109 trials

Trial of INI-4001 in Patients With Advanced Solid Tumours
Recruiting·IInimmune Corporation·Phase 1·NCT06302426·50 enrolled
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours
Recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 1·NCT06697665·10 enrolled
Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours
Recruiting·WWuxi People's Hospital·N/A·NCT06430502·200 enrolled
A Study of EBC-129 in Advanced Solid Tumours
Recruiting·EEDDC (Experimental Drug Development Centre), A*STAR Research Entities·Phase 1·NCT05701527·98 enrolled
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 2·NCT07111546·140 enrolled
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Recruiting·PPhost'In Therapeutics·Phase 1·NCT05495295·149 enrolled
AMT-253 in Patients With Selected Advanced Solid Tumours
Recruiting·MMultitude Therapeutics (Australia) Pty Ltd·Phase 1·NCT05906862·54 enrolled
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT05489211·454 enrolled
Study of STP938 in Advanced Solid Tumours
Recruiting·SStep Pharma, SAS·Phase 1·NCT06297525·70 enrolled
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT06219941·224 enrolled
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours
Recruiting·SShanghai Best-Link Bioscience, LLC·Phase 1·NCT06247657·66 enrolled
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Recruiting·MMonTa Biosciences ApS·Phase 1·NCT04855435·106 enrolled
An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours
Recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 1·NCT06695689·10 enrolled
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 2·NCT06783647·230 enrolled
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Recruiting·LLaNova Medicines Limited·Phase 1/2·NCT06682780·320 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)